{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:33:39Z","timestamp":1778574819364,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"am","delay-in-days":380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.vaccine.2018.04.080","type":"journal-article","created":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T13:37:42Z","timestamp":1525095462000},"page":"3221-3230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program"],"prefix":"10.1016","volume":"36","author":[{"given":"Suzanne M.","family":"Garland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa M.","family":"Cornall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia M.L.","family":"Brotherton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Wark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Malloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sepehr N.","family":"Tabrizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.vaccine.2018.04.080_b0005","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.04.080_b0010","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four trials","volume":"369","author":"The Future II Study Group","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2018.04.080_b0015","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.vaccine.2018.04.080_b0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2018.04.080_b0025","doi-asserted-by":"crossref","unstructured":"Garland SM, Kjaer SK, Mu\u00f1oz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of ten years of real-world experience. Clin Infect Dis 2016;63(4):519\u201327.","DOI":"10.1093\/cid\/ciw354"},{"key":"10.1016\/j.vaccine.2018.04.080_b0030","unstructured":"Human Papillomavirus vaccines: WHO position paper, May 2017. [cited May 2017]; Available from: <http:\/\/apps.who.int\/iris\/bitstream\/10665\/255353\/1\/WER9219.pdf?ua=1>."},{"issue":"3","key":"10.1016\/j.vaccine.2018.04.080_b0035","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1071\/SH09137","article-title":"Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy","volume":"7","author":"Brotherton","year":"2010","journal-title":"Sex Health"},{"key":"10.1016\/j.vaccine.2018.04.080_b0040","author":"National HPV Vaccination Programme Coverage"},{"issue":"6","key":"10.1016\/j.vaccine.2018.04.080_b0045","doi-asserted-by":"crossref","first-page":"262","DOI":"10.5694\/mja16.00958","article-title":"HPV vaccine coverage is increasing in Australia","volume":"206","author":"Brotherton","year":"2017","journal-title":"Med J Aust"},{"issue":"5","key":"10.1016\/j.vaccine.2018.04.080_b0050","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.vaccine.2013.11.075","article-title":"Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: independent estimates from a nationally representative mobile phone survey","volume":"32","author":"Brotherton","year":"2014","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2018.04.080_b0055","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1071\/SH15035","article-title":"Human papillomavirus prevalence to age 60 years amongst Australian women pre-vaccination","volume":"12","author":"Brotherton","year":"2015","journal-title":"Sexual Health"},{"key":"10.1016\/j.vaccine.2018.04.080_b0060","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1741-7015-9-104","article-title":"Human Papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program","volume":"9","author":"Garland","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2018.04.080_b0065","doi-asserted-by":"crossref","unstructured":"Tabrizi SN, Brotherton JML, Kaldor JM, Skinner SR, Cummins E, Liu B, et al. Fall in human papillomavirus prevalence following a national vaccination program. JID 2012;206(11):1645\u201351.","DOI":"10.1093\/infdis\/jis590"},{"issue":"10","key":"10.1016\/j.vaccine.2018.04.080_b0070","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1473-3099(14)70841-2","article-title":"Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study","volume":"14","author":"Tabrizi","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2018.04.080_b0075","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/1471-2407-13-296","article-title":"Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study)","volume":"13","author":"Young","year":"2013","journal-title":"BMC Cancer."},{"issue":"1","key":"10.1016\/j.vaccine.2018.04.080_b0080","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.2196\/jmir.1978","article-title":"Web-based recruiting for health research using a social networking site: an exploratory study","volume":"14","author":"Fenner","year":"2012","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.vaccine.2018.04.080_b0085","unstructured":"Sensis\u00ae. YellowTMSocial Media Report: what Australian people and businesses are doing with social media; 2016. [cited July 2017]; Available from: <https:\/\/www.sensis.com.au\/asset\/PDFdirectory\/Sensis_Social_Media_Report_2016.PDF>."},{"issue":"1","key":"10.1016\/j.vaccine.2018.04.080_b0090","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.vaccine.2014.10.045","article-title":"Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program","volume":"33","author":"Osborne","year":"2015","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2018.04.080_b0095","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1071\/SH15132","article-title":"Opportunities to increase rates of human papillomavirus vaccination in the New South Wales school program through enhanced catch-up","volume":"13","author":"Staples","year":"2016","journal-title":"Sexual Health"},{"issue":"18","key":"10.1016\/j.vaccine.2018.04.080_b0100","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/jnci\/82.18.1477","article-title":"Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers","volume":"82","author":"Resnick","year":"1990","journal-title":"JNCI: J Nat Cancer Inst"},{"key":"10.1016\/j.vaccine.2018.04.080_b0105","doi-asserted-by":"crossref","unstructured":"Ong JJ, Read T, Chen M, Walker S, Law M, Bradshaw C, et al. Improving oral human papillomavirus detection using toothbrush sampling in HIV-positive men who have sex with men. J Clin Microbiol 2014;52(6):2206\u20139.","DOI":"10.1128\/JCM.00286-14"},{"issue":"11","key":"10.1016\/j.vaccine.2018.04.080_b0110","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1128\/JCM.01169-08","article-title":"Validation of an automated detection platform for use with the roche linear array human papillomavirus genotyping test","volume":"46","author":"Stevens","year":"2008","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2018.04.080_b0115","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jviromet.2006.02.007","article-title":"Human papillomavirus genotyping using a modified linear array detection protocol","volume":"135","author":"Stevens","year":"2006","journal-title":"J Virol Methods"},{"issue":"6","key":"10.1016\/j.vaccine.2018.04.080_b0120","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1309\/MPERNJ0G62RECHCQ","article-title":"Evaluation of a modified reverse line blot assay for detection and typing of human papillomavirus","volume":"123","author":"Tabrizi","year":"2005","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.vaccine.2018.04.080_b0125","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jviromet.2007.09.018","article-title":"Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler 480 system","volume":"147","author":"Stevens","year":"2008","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2018.04.080_b0130","unstructured":"Department of Health. NHMRC screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen detected abnormalities; November 2012 [cited 2017]. Available from: <www.nhmrc.gov.au\/publications>."},{"key":"10.1016\/j.vaccine.2018.04.080_b0135","unstructured":"Australian Bureau of Statistics. Table builder basic: 2011 census of population and housing (Cat no. 20720); 2011 [cited 2017]; Available from: <http:\/\/www.abs.gov.au\/websitedbs\/censushome.nsf\/home\/tablebuilder>."},{"key":"10.1016\/j.vaccine.2018.04.080_b0140","unstructured":"Australian Bureau of Statistics: 2033.0.55.001 \u2013 Census of population and housing: socio-economic indexes for areas (SEIFA), Australia; 2011 [cited 2017]; Available from: <http:\/\/www.abs.gov.au\/ausstats\/abs@.nsf\/DetailsPage\/2033.0.55.0012011>."},{"key":"10.1016\/j.vaccine.2018.04.080_b0145","doi-asserted-by":"crossref","unstructured":"Machalek DA, Garland SM, Brotherton JML, Bateson D, McNamee K, Stewart M, et al. Very low prevalence of vaccine human papillomavirus (HPV) types among 18 to 35 year old Australian women, nine years following implementation of vaccination. J Infect Dis 2018:jiy075\u2013jiy.","DOI":"10.1093\/infdis\/jiy075"},{"key":"10.1016\/j.vaccine.2018.04.080_b0150","unstructured":"Machalek DA, Garland SM, Bateson D, McNamee K, Stewart M, Hocking A, et al. Prevalence of genital Hpv in australian women aged 18 to 35 years following implementation of vaccination. The 31st international papillomavirus conference & clinical and public health workshops; Cape Town, South Africa; 2017. Abstract No. 643."},{"key":"10.1016\/j.vaccine.2018.04.080_b0155","doi-asserted-by":"crossref","unstructured":"Haguenoer K, Giraudeau B, Gaudy-Graffin C, de Pinieux I, Dubois F, Trignol-Viguier N, et al. Accuracy of dry vaginal self-sampling for detecting high-risk human papillomavirus infection in cervical cancer screening: a cross-sectional study. Gynecol Oncol 134(2):302\u20138.","DOI":"10.1016\/j.ygyno.2014.05.026"},{"issue":"11","key":"10.1016\/j.vaccine.2018.04.080_b0160","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1099\/jmm.0.046110-0","article-title":"Evaluation of dry and wet transport of at-home self-collected vaginal swabs for human papillomavirus testing","volume":"61","author":"Wolfrum","year":"2012","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2018.04.080_b0165","doi-asserted-by":"crossref","unstructured":"Darlin L, Borgfeldt C, Forslund O, H\u00e9nic E, Dillner J, Kannisto P. Vaginal self-sampling without preservative for human papillomavirus testing shows good sensitivity. J Clin Virol 56(1):52\u20136.","DOI":"10.1016\/j.jcv.2012.09.002"},{"key":"10.1016\/j.vaccine.2018.04.080_b0170","doi-asserted-by":"crossref","unstructured":"Bhatla N, Dar L, Patro AR, Kumar P, Kriplani A, Gulati A, et al. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries? Cancer Epidemiol 2009\/12\/01\/;33(6):446\u201350.","DOI":"10.1016\/j.canep.2009.10.013"},{"issue":"6","key":"10.1016\/j.vaccine.2018.04.080_b0175","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/01.olq.0000240315.19652.59","article-title":"Concordance of self-collected and clinician-collected swab samples for detecting human papillomavirus DNA in women 18 to 32 years of age","volume":"34","author":"Winer","year":"2007","journal-title":"Sex Transm Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2018.04.080_b0180","first-page":"95","article-title":"Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction","volume":"10","author":"Gravitt","year":"2001","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"3","key":"10.1016\/j.vaccine.2018.04.080_b0185","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ygyno.2012.08.033","article-title":"Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial","volume":"127","author":"Bahmanyar","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.vaccine.2018.04.080_b0190","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1542\/peds.2011-3587","article-title":"Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction","volume":"130","author":"Kahn","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.04.080_b0195","doi-asserted-by":"crossref","unstructured":"Donken R, Schurink-van't Klooster TM, Schepp RM, van der Klis FR, Knol MJ, Meijer CJ, et al. Immune responses after two-versus three-doses of HPV vaccination up to 4\u00bd years post vaccination: an observational study among Dutch routinely vaccinated girls (HPV2D). J Infect Dis 2016:jiw588.","DOI":"10.1093\/infdis\/jiw588"},{"key":"10.1016\/j.vaccine.2018.04.080_b0200","doi-asserted-by":"crossref","first-page":"850","DOI":"10.15585\/mmwr.mm6533a4","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 years\u2014United States, 2015","volume":"65","author":"Reagan-Steiner","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"10.1016\/j.vaccine.2018.04.080_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.2015-1968","article-title":"Prevalence of HPV after introduction of the vaccination program in the United States","volume":"137","author":"Markowitz","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.04.080_b0210","doi-asserted-by":"crossref","unstructured":"Dunne EF, Naleway A, Smith N, Crane B, Weinmann S, Braxton J, et al. Reduction in HPV vaccine type prevalence among young women screened for cervical cancer in an integrated health care delivery system, United States 2007, 2012\u20132013. J Infect Dis. 2015:jiv342.","DOI":"10.1093\/infdis\/jiv342"},{"issue":"10","key":"10.1016\/j.vaccine.2018.04.080_b0215","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/cid\/ciw533","article-title":"Substantial decline in vaccine-type human papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a community","volume":"63","author":"Kahn","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.080_b0220","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1158\/1055-9965.EPI-14-0687","article-title":"Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study","volume":"23","author":"S\u00f6derlund-Strand","year":"2014","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"1","key":"10.1016\/j.vaccine.2018.04.080_b0225","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1471-2334-14-87","article-title":"Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling","volume":"14","author":"Deler\u00e9","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2018.04.080_b0230","first-page":"757","article-title":"Effectiveness of human papillomavirus vaccination on prevalence of vaccine genotypes in young sexually active women in France","volume":"215","author":"Heard","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.080_b0235","doi-asserted-by":"crossref","unstructured":"Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis 17(12):1293\u2013302.","DOI":"10.1016\/S1473-3099(17)30468-1"},{"issue":"4","key":"10.1016\/j.vaccine.2018.04.080_b0240","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/CEJ.0000000000000067","article-title":"Early effects of human papillomavirus vaccination in Belgium","volume":"24","author":"Merckx","year":"2015","journal-title":"Eur J Cancer Prev"},{"issue":"1","key":"10.1016\/j.vaccine.2018.04.080_b0245","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S2468-2667(16)30001-9","article-title":"Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models","volume":"1","author":"Brisson","year":"2016","journal-title":"Lancet Public Health"},{"issue":"10","key":"10.1016\/j.vaccine.2018.04.080_b0250","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/infdis\/jix476","article-title":"The impact of human papillomavirus catch-up vaccination in Australia: implications for introduction of multiple age cohort vaccination and postvaccination data interpretation","volume":"216","author":"Drolet","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.080_b0255","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/sti.2009.037788","article-title":"Rapid decline in warts after national quadrivalent HPV vaccine program","volume":"85","author":"Fairley","year":"2009","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2018.04.080_b0260","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f2032","article-title":"Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data","volume":"346","author":"Ali","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2018.04.080_b0265","doi-asserted-by":"crossref","unstructured":"Brotherton JML et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. The Lancet 2011;377(9783):2085\u201392.","DOI":"10.1016\/S0140-6736(11)60551-5"},{"key":"10.1016\/j.vaccine.2018.04.080_b0270","doi-asserted-by":"crossref","unstructured":"Brotherton JML, Gertig DM, May C, Chappell G, M. S. HPV vaccine impact in Australian women: ready for an HPV-based screening program. MJA 2016;204(5):184.","DOI":"10.5694\/mja15.01038"},{"issue":"5","key":"10.1016\/j.vaccine.2018.04.080_b0275","doi-asserted-by":"crossref","first-page":"204","DOI":"10.5694\/mja16.00597","article-title":"Human papillomavirus vaccination and genital warts in young Indigenous Australians: national sentinel surveillance data","volume":"206","author":"Ali","year":"2017","journal-title":"Med J Aust"},{"issue":"1","key":"10.1016\/j.vaccine.2018.04.080_b0280","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2334-13-140","article-title":"Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program","volume":"13","author":"Ali","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2018.04.080_b0285","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/1741-7015-11-227","article-title":"Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study","volume":"11","author":"Gertig","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2018.04.080_b0290","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.30871","article-title":"Looking beyond human papillomavirus (HPV) genotype 16 and 18: defining HPV genotype distribution in cervical cancers in Australia prior to vaccination","author":"Brotherton","year":"2017","journal-title":"Int J Cancer"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18305875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18305875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:27:51Z","timestamp":1759400871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18305875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":58,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0264410X18305875"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.080","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}